Name: Processing of Human Cardiac Tissue Toward Extracellular Matrix Self-assembling Hydrogel for In Vitro and In Vivo Applications (Video) | JoVE Journal
Uploaded: 2017-12-04T14:00:00.000+00:00
Duration: 8 min 41 s
Description: Learn to process human cardiac extracellular matrix into a self-assembling hydrogel for cell-based assays. This decellularization method preserves matrix components to study cell behavior and advance cardiac regeneration research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The study protocol conforms to the ethical principles outlined in the Declaration of Helsinki. Patients provided informed consent for the use of the tissue for research purposes, and the process of tissue collection was approved by the Institutional Review Board and ethics committee of Charit&#233; - Universit&#228;tsmedizin Berlin (EA4/028/12).

The study protocol conforms to the ethical principles outlined in the Declaration of Helsinki and was approved by the institutional review board and ethics committee of Charit&#233; Medical University. All patients provided written, informed consent for use of heart tissue for experimental studies.
1. Preparation of Human Myocardium for Sectioning
<ol>
	<li>Obtain left ventricular myocardium (size varies depending on the type of surgery) directly from the operating room and transport in cold PBS in a sterile container.</li>
	<li>Remove all fat tissue with a sterile scalpel with a no. 10 blade under sterile conditions.</li>
	<li>Cut the myocardium in cubes of approximately 1 x 1 x 1 cm using a scalpel.</li>
	<li>Place the cubes in sterile 50 mL tubes. 
	NOTE: To pause, perform step 1.5, otherwise continue with step 2.2. Avoid repeated freeze-thaw cycles to prevent protein degradation and a decrease in tissue quality.</li>
	<li>Store the tubes containing the cubes at -80 &#176;C. The tissue can be stored for several months.</li>
</ol>
2. Sectioning of the Myocardium Cubes into Slices
<ol>
	<li>Take the tube(s) containing the prepared cubes out of the freezer.</li>
	<li>Transport on ice to the cryostat.</li>
	<li>Set the object and chamber temperature to -15 &#176;C. 
	NOTE: The right temperature is crucial to guarantee perfect sectioning.</li>
	<li>Chill empty 50 mL tubes and stamps in the chamber or on dry ice.</li>
	<li>Add a layer (approximately 0.5 - 1.0 mL) of cryosection medium onto the cold stamp and let it freeze until it is white and solid.</li>
	<li>Add a second layer of cryosection medium and place a myocardium cube onto this layer.</li>
	<li>Make sure the cryosection medium and myocardium are completely frozen before you continue. 
	NOTE: When the sample and cryosection medium are not frozen the sectioning will be impaired. Completely frozen cryosection medium turns from fluid and transparent to solid, white, and non-transparent. The myocardial cubes need at least 30 min up to 1 h to completely freeze if continuing immediately from step 1.4. When the tissue is frozen it should not deform when touched/handled with tweezers.</li>
	<li>Insert stamp with frozen myocardium into the holder and tighten all screws.</li>
	<li>Trim the surface of the tissue until an even sectioning surface is obtained.</li>
	<li>Set sectioning thickness to 300 &#181;m.</li>
	<li>Section the frozen myocardium with automatic sectioning. This guarantees uniform cut sections. Approximately 30 - 40 sections can be sliced from one cube.</li>
	<li>Place each slice after sectioning loosely in a precooled 50 mL tube. 
	NOTE: Do not press the slices or pack tightly. Approximately 40 slices can fit in one tube.</li>
	<li>Close the filled tubes and place on ice. 
	NOTE: To pause go on with step 2.14, otherwise continue with step 3.2.</li>
	<li>Store myocardium slices at -80 &#176;C. The slices can be stored for several months.</li>
</ol>
3. Decellularization of Human Myocardium Slices
<ol>
	<li>Take the necessary number of 50 mL tubes containing myocardium sections out of the -80 &#176;C freezer and transport on ice.</li>
	<li>Transfer the frozen sections of all 50 mL tubes from step 3.1 into one sterile beaker. Approximately 40 slices are added to the beaker per 50 mL tube. The beaker should be three times the volume of the 50 mL tubes; for example, for decellularization of one 50 mL tube use a 150 mL beaker.</li>
	<li>Add 50 mL lysis solution (10 mM Tris, 0.1% w/v EDTA, pH 7.4 in H2O) per 50 mL tube with myocardium slices.</li>
	<li>Shake the myocardium slices in a sterile beaker at 100 - 150 rpm continuously for 2 h at room temperature.</li>
	<li>Strain the liquid with the tissue slices through a coarse strainer. Transfer the tissue slices with a blunt tweezer to a new sterile beaker. Add 50 mL of 0.5% SDS in PBS per initial 50 mL tube of myocardium slices (e.g., use 100 mL SDS solution when two 50 mL tubes of myocardial sections are being decellularized).</li>
	<li>Shake continuously for 6 h at 100 - 150 rpm at room temperature.</li>
	<li>Strain the liquid with the tissue slices through a coarse strainer. Transfer the tissue slices with a blunt tweezer to a new sterile beaker and wash 3 times with 50 mL PBS for 10 min each while shaking at 150 rpm. Next, wash overnight in PBS with 1% Penicillin/Streptomycin and 1% Nystatin (PBS-P/S-N) at 100-150 rpm and 4 &#176;C while shaking. 
	NOTE: Thorough washing is crucial to completely remove any residual SDS. Remaining traces of SDS are toxic when the ECM is used in combination with cells.</li>
	<li>Remove the washing solution and add 25 mL preheated FBS (37 &#176;C) with 1% Penicillin/Streptomycin and 1% Nystatin to the decellularized slices per initial 50 mL tube of myocardium slices.</li>
	<li>Incubate for 3 h at 37 &#176;C. In this step, any remaining DNA is removed from the matrix due to the intrinsic DNase activity of the FBS.</li>
	<li>Transfer the slices to a new sterile beaker and wash 3 times with 50 mL PBS for 10 min each while shaking at 150 rpm. 
	NOTE: The ECM slices can be stored in PBS-P/S-N at 4 &#176;C for several days. However, it is recommended to proceed immediately.</li>
</ol>
4. Processing the Decellularized cECM to a Powder
<ol>
	<li>Place the ECM slices loosely in a new sterile 6-well plate. Freeze the ECM at -80 &#176;C and lyophilize for 2 days in a lyophilizer. 
	NOTE: More than one slice can be placed per well. Arrange the slices to completely cover the surface of the well. Overlapping the slices does not affect the subsequent pulverization success.</li>
	<li>For the pulverization of the ECM slice, use specific milling tubes (see Table of Materials) containing 1.4 mm ceramic beads.Fill the tubes loosely with lyophilized ECM using sterile blunt tweezers. For optimal results, a total weight of ECM between 10 - 20 mg is recommended. 
	NOTE: If the ECM is packed too tightly in the milling tubes the pulverization process will be negatively affected.</li>
	<li>Snap-freeze the tubes in liquid nitrogen. 
	CAUTION: Liquid nitrogen is extremely low temperature, wear appropriate personal protection.</li>
	<li>Insert the frozen tubes into the milling machine and pulverize the ECM.
	<ol>
		<li>Set a duration of 30 s and a maximum speed and start the device.</li>
		<li>After finishing, take out the tubes and snap-freeze again in liquid nitrogen.</li>
		<li>Repeat five times.</li>
	</ol>
	</li>
	<li>Wash the microparticles from the tubes by adding 1 mL ddH2O per tube and shake or vortex for complete solubilizing. Filter the heterogeneous solution through a 200 &#181;m mesh into a 50 mL tube.</li>
	<li>Freeze the tube in -80 &#176;C or liquid nitrogen.</li>
	<li>Replace the standard lid of the tube with a 0.22 &#181;m filter. This filter lid prevents the powder from flowing out of the tube but allows air circulation for water evaporation.</li>
	<li>Insert the tubes in the lyophilizer and lyophilize again to remove the water from the step (step 4.5) 
	NOTE: Lyophilization at this step can take up to 3 days.</li>
	<li>Store powder at -80 &#176;C until further processing or continue with step 5.1.</li>
</ol>
5. Enzyme Based Homogenizing of cECM Micro-Particles
<ol>
	<li>Dissolve porcine pepsin in 0.01M HCl (pH 2.0) to a concentration of 1 mg/mL. Place on a rotary shaker at room temperature until it is completely dissolved.</li>
	<li>Dissolve the lyophilized human ECM powder (Step 4.8) in the pepsin solution to a final concentration of 10 mg/mL. Mix thoroughly through pipetting. The total volume depends on the amount of ECM solution needed. For example, dissolve 10 mg of ECM powder in 1 mL pepsin solution. 
	NOTE: Dissolving particles can be supported through gentle vortexing (1,000 - 1,500 RPM). Remaining lumps of microparticles will negatively affect the digestion.</li>
	<li>Transfer the solution to 2 mL tubes with a volume of 1 mL per tube.</li>
	<li>Place the tubes in a tube shaker for 48 h at 27 &#176;C and 1,200 rpm.</li>
	<li>Take the tubes out of the shaker and place on ice or a pre-cooled tube holder.</li>
	<li>Mix 1/9 of the volume of ECM solution of cold 10x PBS (pH 7.4) with 1/10 of the volume of ECM solution of cold 0.1M NaOH in a precooled tube and place on ice. This mixture will neutralize the digested ECM solution and irreversibly inactivate the pepsin.</li>
	<li>Add the ECM solution to the neutralization mixture and mix thoroughly through pipetting or vortexing.</li>
	<li>Set the ECM to the desired concentration with 1x PBS (pH 7.4). The pH of the solution can be checked with pH paper. 
	NOTE: Example calculation for 10 mL digested ECM solution: 
	Add 10 mg porcine pepsin to 10 mL HCl (pH 2.0). 
	Add 100 mg ECM powder to pepsin solution. 
	NOTE: Example calculation for neutralizing 10 mL digested ECM solution and setting the concentration to 8 mg/mL: 
	VolFinal = cstart x Volstart / cFinal = 10 mg/mL x 10 mL / 8 mg/mL = 12.5 mL 
	Vol10xPBS = Volstart / 9 = 1/9 from 10 mL = 1.11 mL 10x PBS 
	VolNaOH = Volstart / 10 = 1/10 from 10 mL = 1 mL 
	Vol1xPBS = VolFinal - Volstart - Vol10xPBS - VolNaOH = 12.5 mL - 10 mL - .11 mL - 1 mL = 0.39 mL</li>
</ol>

<ol><li>Elliott, R., Hoehn, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+Commercial+Porcine+Skin+for+Wound+Dressings%5BTitle%5D)+AND+%22Plastic+and+reconstructive+surgery%22%5BJournal%5D)">Use of Commercial Porcine Skin for Wound Dressings.</a> Plastic and reconstructive surgery. 52 (4), 401-405 (1973).</li>
<li>Rienks, M., Papageorgiou, A. -P., Frangogiannis, N. G., Heymans, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Myocardial+Extracellular+Matrix%3A+An+Ever-Changing+and+Diverse+Entity%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity.</a> Circulation Research. 114 (5), 872-888 (2014).</li>
<li>Prabhu, S. D., Frangogiannis, N. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+Biological+Basis+for+Cardiac+Repair+After+Myocardial+Infarction%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">The Biological Basis for Cardiac Repair After Myocardial Infarction.</a> Circulation Research. 119 (1), 91-112 (2016).</li>
<li>Boopathy, A. V., Martinez, M. D., Smith, A. W., Brown, M. E., Garcia, A. J., Davis, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intramyocardial+Delivery+of+Notch+Ligand-Containing+Hydrogels+Improves+Cardiac+Function+and+Angiogenesis+Following+Infarction%5BTitle%5D)+AND+%22Tissue+Eng+Part+A%22%5BJournal%5D)">Intramyocardial Delivery of Notch Ligand-Containing Hydrogels Improves Cardiac Function and Angiogenesis Following Infarction.</a> Tissue Eng Part A. 21 (17-18), 2315-2322 (2015).</li>
<li>Gaetani, R., Yin, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cardiac+derived+extracellular+matrix+enhances+cardiogenic+properties+of+human+cardiac+progenitor+cells%5BTitle%5D)+AND+%22Cell+Transplant%22%5BJournal%5D)">Cardiac derived extracellular matrix enhances cardiogenic properties of human cardiac progenitor cells.</a> Cell Transplant. , (2015).</li>
<li>Kraehenbuehl, T. P., Ferreira, L. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+embryonic+stem+cell-derived+microvascular+grafts+for+cardiac+tissue+preservation+after+myocardial+infarction%5BTitle%5D)+AND+%22Biomaterials%22%5BJournal%5D)">Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction.</a> Biomaterials. 32 (4), 1102-1109 (2011).</li>
<li>Zhang, J., Klos, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extracellular+matrix+promotes+highly+efficient+cardiac+differentiation+of+human+pluripotent+stem+cells%3A+The+matrix+sandwich+method%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: The matrix sandwich method.</a> Circulation Research. 111 (9), 1125-1136 (2012).</li>
<li>Fong, A. H., Romero-López, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Three-Dimensional+Adult+Cardiac+Extracellular+Matrix+Promotes+Maturation+of+Human+Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes%5BTitle%5D)+AND+%22Tissue+Engineering+Part+A%22%5BJournal%5D)">Three-Dimensional Adult Cardiac Extracellular Matrix Promotes Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.</a> Tissue Engineering Part A. 22 (15-16), 1016-1025 (2016).</li>
<li>DeQuach, J. A., Mezzano, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Simple+and+High+Yielding+Method+for+Preparing+Tissue+Specific+Extracellular+Matrix+Coatings+for+Cell+Culture%5BTitle%5D)+AND+%22PLoS+ONE%22%5BJournal%5D)">Simple and High Yielding Method for Preparing Tissue Specific Extracellular Matrix Coatings for Cell Culture.</a> PLoS ONE. 5 (9), e13039(2010).</li>
<li>Saldin, L. T., Cramer, M. C., Velankar, S. S., White, L. J., Badylak, S. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extracellular+matrix+hydrogels+from+decellularized+tissues%3A+Structure+and+function%5BTitle%5D)+AND+%22Acta+Biomaterialia%22%5BJournal%5D)">Extracellular matrix hydrogels from decellularized tissues: Structure and function.</a> Acta Biomaterialia. 49, 1-15 (2017).</li>
<li>Tukmachev, D., Forostyak, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Injectable+extracellular+matrix+hydrogels+as+scaffolds+for+spinal+cord+injury+repair%5BTitle%5D)+AND+%22Tissue+Eng+Part+A%22%5BJournal%5D)">Injectable extracellular matrix hydrogels as scaffolds for spinal cord injury repair.</a> Tissue Eng Part A. , (2016).</li>
<li>Freytes, D. O., Martin, J., Velankar, S. S., Lee, A. S., Badylak, S. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+and+rheological+characterization+of+a+gel+form+of+the+porcine+urinary+bladder+matrix%5BTitle%5D)+AND+%22Biomaterials%22%5BJournal%5D)">Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix.</a> Biomaterials. 29 (11), 1630-1637 (2008).</li>
<li>Singelyn, J. M., Sundaramurthy, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Catheter-deliverable+hydrogel+derived+from+decellularized+ventricular+extracellular+matrix+increases+endogenous+cardiomyocytes+and+preserves+cardiac+function+post-myocardial+infarction%5BTitle%5D)+AND+%22Journal+of+the+American+College+of+Cardiology%22%5BJournal%5D)">Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction.</a> Journal of the American College of Cardiology. 59 (8), 751-763 (2012).</li>
<li>Wainwright, J. M., Czajka, C. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+of+cardiac+extracellular+matrix+from+an+intact+porcine+heart%5BTitle%5D)+AND+%22Tissue+Eng+Part+C+Methods%22%5BJournal%5D)">Preparation of cardiac extracellular matrix from an intact porcine heart.</a> Tissue Eng Part C Methods. 16 (3), 525-532 (2010).</li>
<li>Ott, H. C., Matthiesen, T. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Perfusion-decellularized+matrix%3A+using+nature%27s+platform+to+engineer+a+bioartificial+heart%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart.</a> Nature Medicine. 14, 213-221 (2008).</li>
<li>Oberwallner, B., Anic, B. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+cardiac+extracellular+matrix+supports+myocardial+lineage+commitment+of+pluripotent+stem+cells%5BTitle%5D)+AND+%22Eur+J+Cardiothorac+Surg%22%5BJournal%5D)">Human cardiac extracellular matrix supports myocardial lineage commitment of pluripotent stem cells.</a> Eur J Cardiothorac Surg. 47, 416-425 (2015).</li>
<li>Oberwallner, B., Brodarac, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+of+cardiac+extracellular+matrix+scaffolds+by+decellularization+of+human+myocardium%5BTitle%5D)+AND+%22Journal+of+Biomedical+Materials+Research+Part+A%22%5BJournal%5D)">Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium.</a> Journal of Biomedical Materials Research Part A. 102 (9), 3263-3272 (2014).</li>
<li>Kappler, B., Anic, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+cytoprotective+capacity+of+processed+human+cardiac+extracellular+matrix%5BTitle%5D)+AND+%22Journal+of+Materials+Science%3A+Materials+in+Medicine%22%5BJournal%5D)">The cytoprotective capacity of processed human cardiac extracellular matrix.</a> Journal of Materials Science: Materials in Medicine. , (2016).</li>
<li>Bashey, R. I., Martinez-Hernandez, A., Jimenez, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation%2C+characterization%2C+and+localization+of+cardiac+collagen+type+VI.+Associations+with+other+extracellular+matrix+components%5BTitle%5D)+AND+%22Circulation+Research%22%5BJournal%5D)">Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components.</a> Circulation Research. 70 (5), (1992).</li>
<li>Wu, J., Ravikumar, P., Nguyen, K. T., Hsia, C. C. W., Hong, Y., Gorler, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+protection+by+inhalation+of+exogenous+solubilized+extracellular+matrix%5BTitle%5D)+AND+%22PLOS+ONE%22%5BJournal%5D)">Lung protection by inhalation of exogenous solubilized extracellular matrix.</a> PLOS ONE. 12 (2), e0171165(2017).</li>
<li>Chen, W. C. W., Wang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Decellularized+zebrafish+cardiac+extracellular+matrix+induces+mammalian+heart+regeneration%5BTitle%5D)+AND+%22Science+Advances%22%5BJournal%5D)">Decellularized zebrafish cardiac extracellular matrix induces mammalian heart regeneration.</a> Science Advances. 2 (11), e1600844(2016).</li>
<li>Godier-Furnémont, A. F. G., Martens, T. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Composite+scaffold+provides+a+cell+delivery+platform+for+cardiovascular+repair%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Composite scaffold provides a cell delivery platform for cardiovascular repair.</a> Proceedings of the National Academy of Sciences of the United States of America. 108 (19), 7974-7979 (2011).</li>
<li>Sarig, U., Sarig, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Natural+myocardial+ECM+patch+drives+cardiac+progenitor+based+restoration+even+after+scarring%5BTitle%5D)+AND+%22Acta+Biomaterialia%22%5BJournal%5D)">Natural myocardial ECM patch drives cardiac progenitor based restoration even after scarring.</a> Acta Biomaterialia. 44, 209-220 (2016).</li>
<li>Singelyn, J. M., DeQuach, J. A., Seif-Naraghi, S. B., Littlefield, R. B., Schup-Magoffin, P. J., Christman, K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Naturally+derived+myocardial+matrix+as+an+injectable+scaffold+for+cardiac+tissue+engineering%5BTitle%5D)+AND+%22Biomaterials%22%5BJournal%5D)">Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering.</a> Biomaterials. 30 (29), 5409-5416 (2009).</li>
</ol>

The authors have nothing to disclose.

When preparing human myocardial ECM, the goal is to achieve the following: removal of relevant immunogenic cellular material, preservation of ECM integrity and bioactivity, sterility, non-toxicity of the end-product, GMP-process compatibility, and suitability of the product for a given application in terms of handling. By combining our 3-step decellularization protocol with further processing into microparticles or self-assembling hydrogel, human cardiac ECM material is obtained that possesses specific biological activit...

The extracellular matrix (ECM) provides not only structural support but is also important for biologic cell and tissue function1. In the heart, the ECM participates in the regulation of pathophysiologic responses such as fibrosis, inflammation, angiogenesis, cardiomyocyte contractile function and viability, and resident progenitor cell fate. In addition to its primary components - fibrous glycoproteins, glycosaminoglycans, and proteoglycans - it contains a host of secreted growth factors, cytokines, and membranous vesicles containing nucleic acids and proteins2,3.
It has recently become clear that acellular ECM preparations are not only invaluable for studying cell-matrix interactions, but also for potential therapeutic cell-based applications. The importance of providing an adequate environment to therapeutic cell products or engineered tissues is now widely acknowledged. Attempts have been made to combine cell suspensions or active compounds with defined biopolymeric hydrogels4,5,6 or with protein cocktails secreted by murine sarcoma cells (i.e., Matrigel, Geltrex)7. However, the former have limited bioactivity, the latter are problematic in GMP-grade processes, and both lack the tissue-specific bioactivity of cardiac ECM (cECM)8,9,10,11,12,13.
Decellularization of the myocardium has previously been performed by perfusion of the whole heart via the coronary vasculature14,15. While this is possible in animal hearts, intact human hearts are rarely available. Therefore, an immersion process that allows for handling tissue samples obtained in the operating room was favored. Our &#34;3-step&#34; protocol contains 3 separate incubation steps namely lysis, solubilization, and DNA removal. It yields human myocardial ECM with largely preserved protein and glycosaminoglycan composition16,17. These cECM slices allow for in vitro studies of cell-matrix interactions but are poorly suited for potential human-scale therapeutic applications. The manufacturing process was then extended to produce either lyophilized cECM microparticles or a cECM hydrogel18.
This protocol allows for the decellularization of human myocardium obtained from surgical samples, preserving the major components of myocardial extracellular matrix (ECM) and their biologic activity. This protocol is recommended when human cardiac ECM with preserved tissue-specific bioactivity is required for experimental studies of cell-matrix interactions, or when a suitable environment is needed for cell-based myocardial regeneration approaches. In principle, it is also possible to adapt this protocol to GMP-grade conditions, so that the use of processed cECM should be feasible in future therapeutic applications.

<table><tbody><tr><td>Balance</td><td>DR Precisa, Dietikon, Switzerland</td><td>Precisa XR 205SM</td><td></td></tr><tr><td>Blades Nr.10 Skalpell Nr.3</td><td>InstrumenteNRW, Erftstadt, Germany</td><td>SK-10-004</td><td></td></tr><tr><td>Cell culture plates (6-well)</td><td>Greiner, Frickenhausen, Germany</td><td>657160</td><td></td></tr><tr><td>Cryostat CM</td><td>Leica, Wetzlar, Germany</td><td>3050S</td><td></td></tr><tr><td>EDTA</td><td>Carl Roth, Karlsruhe, Germany</td><td>8043.3</td><td></td></tr><tr><td>Eppendorf reaction tubes (1.5 or 2 ml)</td><td>Greiner, Frickenhausen, Germany</td><td>616201, 623201</td><td></td></tr><tr><td>Falcon 15ml, 50ml</td><td>Greiner, Frickenhausen, Germany</td><td>188271, 227270</td><td></td></tr><tr><td>Fetal Bovine Serum (FBS)</td><td>Biochrome, Berlin, Germany</td><td>S 0115</td><td></td></tr><tr><td>Freeze Dry System</td><td>Labconco, Kansas City, USA</td><td>7670520</td><td></td></tr><tr><td>Freezer (-80&amp;deg;C)</td><td>Thermo Scientific, Waltham, MA, USA</td><td>Forma 900 Series</td><td></td></tr><tr><td>HCl</td><td>Carl Roth, Karlsruhe, Germany</td><td>281.1</td><td></td></tr><tr><td>Microtome Blades Type 819</td><td>Leica, Wetzlar, Germany</td><td>14035838925</td><td></td></tr><tr><td>Minilys Homogeniser</td><td>PEQLAB Biotechnologie GmbH, Erlangen, Germany</td><td>91-PCSM</td><td></td></tr><tr><td>NaOH</td><td>Carl Roth, Karlsruhe, Germany</td><td>K021.1</td><td></td></tr><tr><td>Nystatin</td><td>PAN Biotech, Aidenbach, Germany</td><td>P06-07800</td><td></td></tr><tr><td>PBS</td><td>Thermo Scientific, Waltham, MA, USA</td><td>14190-094</td><td></td></tr><tr><td>Penicillin/streptomycin</td><td>Life Technologies, Darmstadt, Germany</td><td>15140122</td><td></td></tr><tr><td>Pepsin</td><td>Sigma-Aldrich, Taufkirchen, Germany</td><td>P6887-1G</td><td></td></tr><tr><td>Precellys Keramik-Kit 1.4 mm</td><td>Peqlab Biotechnolgie, Erlangen, Germany</td><td>91-PCS-CK14</td><td></td></tr><tr><td>Rotamax 120 Plate shaker</td><td>Heidolph, Schwabach, Germany</td><td>544-41200-00</td><td></td></tr><tr><td>SDS</td><td>Carl Roth, Karlsruhe, Germany</td><td>CN30.3</td><td></td></tr><tr><td>Stereo microscope</td><td>Leica, Wetzlar, Germany</td><td>M125</td><td></td></tr><tr><td>Steriflip-GP, 0,22 &amp;micro;m</td><td>Merck Millipore, Darmstadt, Germany</td><td>SCGP00525</td><td></td></tr><tr><td>Stuart analogue rocker &amp;amp; roller mixers</td><td>Sigma-Aldrich, Taufkirchen, Germany</td><td>Z675113-1EA</td><td></td></tr><tr><td>Tissue Tek O.C.T compound</td><td>Hartenstein, Wurzburg, Germany</td><td>TTEK</td><td></td></tr><tr><td>Transfusion set 200&amp;micro;m</td><td>Sarstedt, N&amp;uuml;mbrecht, Germany</td><td>798.200.500</td><td></td></tr><tr><td>TRIS</td><td>Carl Roth, Karlsruhe, Germany</td><td>5429.3</td><td></td></tr><tr><td>vedena Skalpellgriff Fig. 3, Standard, 125 mm</td><td>Medical Highlights, Rohrdorf, Germany</td><td>CV102-003</td><td></td></tr><tr><td>Vortex-Genie2</td><td>Scientific Industry, New York, USA</td><td>SI-0256</td><td></td></tr></tbody></table>

processing of human cardiac tissue toward extracellular matrix self-assembling hydrogel for in vitro and in vivo applications

Processing of Human Cardiac Tissue Toward Extracellular Matrix Self-assembling Hydrogel for In Vitro and In Vivo Applications

Acellular extracellular matrix preparations are useful for studying cell-matrix interactions and facilitate regenerative cell therapy applications. Several commercial extracellular matrix products are available as hydrogels or membranes, but these do not possess tissue-specific biological activity. Because perfusion decellularization is usually not possible with human heart tissue, we developed a 3-step immersion decellularization process. Human myocardial slices procured during surgery are first treated with detergent-free hyperosmolar lysis buffer, followed by incubation with the ionic detergent, sodium dodecyl sulfate, and the process is completed by exploiting the intrinsic DNase activity of fetal bovine serum. This technique results in cell-free sheets of cardiac extracellular matrix with largely preserved fibrous tissue architecture and biopolymer composition, which were shown to provide specific environmental cues to cardiac cell populations and pluripotent stem cells. Cardiac extracellular matrix sheets can then be further processed into a microparticle powder without further chemical modification, or, via short-term pepsin digestion, into a self-assembling cardiac extracellular matrix hydrogel with preserved bioactivity.

The 3-step protocol for decellularization of human myocardium presented here results in near-complete removal of cellular material, while preserving the key ECM components and the fibrillar structure of ECM. After decellularization, the gross removal of cells from the tissue is evident by the change in color (Figure 1A). Histological analysis with H&amp;E and Masson Trichrome stains revealed the complete absence of residual intact cells (...

This protocol describes the complete decellularization of human myocardium while preserving its extracellular matrix components. Further processing of the extracellular matrix results in the production of microparticles and a cytoprotective self-assembling hydrogel.

Acellular extracellular matrix preparations are useful for studying cell-matrix interactions and facilitate regenerative cell therapy applications. ...

processing-human-cardiac-tissue-toward-extracellular-matrix-self

Research

JoVE Journal

Developmental Biology

Methods for preparing an injectable matrix gel from decellularized tissue and injecting it into rat myocardium in vivo are described.

Fabrication of Biologically Derived Injectable Materials for Myocardial Tissue Engineering

We describe the isolation of neonatal cardiomyocytes and the preparation of the cells for encapsulation in fibrin hydrogel constructs for tissue engineering.  We describe methods for analyzing the tissue engineered myocardium after the culture period including active force generated upon electrical stimulation and cell viability and immunohistological staining.

Encapsulation of Cardiomyocytes in a Fibrin Hydrogel for Cardiac Tissue Engineering 

This manuscript describes the creation of defined engineered cardiac tissues using surface marker expression and cell sorting. The defined tissues can then be used in a multi-tissue bioreactor to investigate mechanisms of cardiac cell therapy in order to provide a functional, yet controlled, model system of the human heart.

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Here, we show the generation of human engineered heart tissue from induced pluripotent stem cells (hiPSC)-derived cardiomyocytes. We present a method to analyze contraction force and exemplary alteration of contraction pattern by the hERG channel inhibitor E-4031. This method shows high level of robustness and suitability for cardiac drug screening.

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

This method enables decellularization of a complex solid organ using a simple protocol based on osmotic shock and perfusion of ionic detergent with minimal organ matrix disruption. It comprises a novel decellularization technique for human hearts inside a pressurized pouch with real-time monitoring of flow dynamics and cellular debris outflow.

Decellularization of Whole Human Heart Inside a Pressurized Pouch in an Inverted Orientation

The present protocol generates mesh-shaped engineered cardiac tissues containing cardiovascular cells derived from human induced pluripotent stem cells to allow the investigation of cell implantation therapy for heart diseases.

Preparation of Mesh-Shaped Engineered Cardiac Tissues Derived from Human iPS Cells for In Vivo Myocardial Repair

Stem cell-based therapy has emerged as an efficient strategy to repair injured cardiac tissues after myocardial infarction. We provide an optimal in vivo application for stem cell transplantation using gelatin hydrogels that are able to be enzymatically cross-linked.

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

The goal of this protocol is to explain and demonstrate the development of a three-dimensional (3D) microfluidic model of highly aligned human cardiac tissue, composed of stem cell-derived cardiomyocytes co-cultured with cardiac fibroblasts (CFs) within a biomimetic, collagen-based hydrogel, for applications in cardiac tissue engineering, drug screening, and disease modeling.

Developing 3D Organized Human Cardiac Tissue within a Microfluidic Platform

Presented here is a set of protocols for the generation and cryopreservation of cardiac spheroids (CSs) from human-induced pluripotent stem cell-derived cardiomyocytes cultured in a high-throughput, multidimensional format. This three-dimensional model functions as a robust platform for disease modeling, high-throughput screenings, and maintains its functionality after cryopreservation.

Generation, High-Throughput Screening, and Biobanking of Human-Induced Pluripotent Stem Cell-Derived Cardiac Spheroids

Fibroblasts isolated from the adult human heart were cultured to confluence on gelatin-coated dishes to produce the myocardium-specific extracellular matrix. After decellularization, this substrate can be used for the culture and study of other cardiac cells and cell-matrix interactions.

Production of Cardiac Extracellular Matrix from Adult Human Fibroblasts for Culture Dish Coating

A reproducible method is presented to generate 3D myocardial tissues combining melt electrospinning writing (MEW) polycaprolactone (PCL) scaffolds and fibrin hydrogels with hiPSC-derived cardiomyocytes and fibroblasts. This technique offers precise control over scaffold architecture and can be applied in preclinical drug testing and cardiac disease modeling.

3D Human Myocardial Tissue Generation Using Melt Electrospinning Writing of Polycaprolactone Scaffolds and hiPSC-Derived Cardiac Cells

Learn to process human cardiac extracellular matrix into a self-assembling hydrogel for cell-based assays. This decellularization method preserves matrix components to study cell behavior and advance cardiac regeneration research.

Processing of Human Cardiac Tissue Toward Extracellular Matrix Self-assembling Hydrogel for In Vitro and In Vivo Applications

Explore More Videos